Reports preliminary adjusted EBITDA of approximately $588M. Sees FY25 revenue of $11.5B-$12B, consensus $12.39B. Sees FY25 adjusted EBITDA of $540M-$555M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $22 from $20 at Mizuho
- BrightSpring Health price target raised to $20 from $19 at Morgan Stanley
- BrightSpring Health initiated with an Outperform at CJS Securities
- BrightSpring Health Services Achieves Major Loan Refinancing
- BrightSpring Health price target raised to $21 from $19 at BofA